Introduction
============

Alzheimer\'s disease (AD) affects millions worldwide and is associated with tremendous human and financial costs. Because the prevalence of AD is increasing and no medications alter disease progression, there is great need for new therapies. Developing these therapies relies upon the clinical trial, but AD trials face challenges. This review focuses on the challenges to effective recruitment and retention of participants. The failure to address these challenges has a number of costs. It can halt a trial, render a scientific question unanswered, and waste precious resources\--most critically the time, effort, and health of participants.

After a review of the literature and experiences in AD clinical trial conduct, this paper summarizes the challenges related to AD trial recruitment and retention for phase II and phase III randomized, placebo-controlled trials of treatments that target the underlying biology or cognitive symptoms associated with AD. We discuss how trial design and conduct can affect recruitment. We examine why recruited participants may not adequately represent the greater disease-suffering population. We overview the barriers to recruitment related to the study participants: both AD patients and their study partners. We discuss the challenges to retention of participants in AD trials. To address these issues, we propose changes to study recruitment practices and attempt to guide investigators to consider potential pitfalls in the way they conduct recruitment and retention.

Trial design and conduct can affect recruitment
===============================================

Success in meeting enrollment goals is not simply about advertising and outreach. Studies that are too long, require too many visits, or target enrollment of a population too difficult to recruit are in danger of slow or inadequate enrollment. In Table [1](#T1){ref-type="table"}, we provide a literature summary of the rates of recruitment to a sample of multicenter AD trials. For these trials, we have calculated a summary recruitment rate statistic (RR) that is an approximation of the number of subjects recruited per study site per month for a given trial. Every trial faces unique challenges to recruitment, and every trial has its own recruitment goals. As such, comparisons among trials must be made carefully. Moreover, the data within Table [1](#T1){ref-type="table"} speak only to the rapidity with which a trial reached full enrollment. Timely fulfillment of the proposed study enrollment is only one part of a truly \'successful\' recruitment. Perhaps more important is the recruitment of a population of participants who are likely to complete the trial, are indeed afflicted with AD, and are representative of others with AD who will not be enrolled. Within a given trial, choices related to study design have a major impact on whether a trial achieves successful enrollment.

###### 

Recruitment rates from a sample of Phase II and Phase III Alzheimer\'s disease clinical trials

                                 Treatment under study                        Study enrollment   Sites   Enrollment, months   **RR**^**a**^   Screened   **Screen ratio**^**b**^
  ------------------------------ -------------------------------------------- ------------------ ------- -------------------- --------------- ---------- -------------------------
  Mild cognitive impairment      Rofecoxib \[[@B54]\]                         1,457              46      24                   1.32            2,849      1.95
                                 Rivastigmine \[[@B55]\]                      1,018              65      12                   1.30            1,526      1.50
                                 Two studies of galantamine \[[@B56]\]        2,057              177     12                   0.97            2,759      1.35
                                 Donepezil \[[@B57]\]                         270                22      16                   0.77            588        2.18
                                 Vitamin E and donepezil \[[@B38]\]           790                69      23                   0.49            2,264      2.87
                                 TRIMCI study of trifusal \[[@B7]\]           257^c^             29      24                   0.36            NA         NA
                                 Donepezil \[[@B58]\]                         821                91      28                   0.32            2,037      2.48
  Mild-to-moderate AD            Dimebon \[[@B59]\]                           183                11      6                    2.77            230        1.26
                                 Idebenone \[[@B60]\]                         536                39      12                   1.14            729        1.36
                                 DHA (Joseph Quinn, personal communication)   402                52      8                    0.96            555        1.39
                                 AN1792 \[[@B61]\]                            372                28      16                   0.83            NA         NA
                                 Rofecoxib \[[@B37]\]                         351                40      11                   0.80            474        1.35
                                 Tarenfl urbil \[[@B9]\]                      1,684              133     21                   0.60            2,408      1.43
                                 Gamma secretase inhibitor \[[@B62]\]         51                 6       51                   0.57            71         1.39
                                 Rivastigmine patch \[[@B63],[@B64]\]         1,195              100     22                   0.54            1,464      1.22
                                 Bapineuzumab \[[@B10]\]                      234                30      16                   0.49            317        1.35
                                 Rosiglitazone \[[@B65]\]                     518                67      17                   0.45            687        1.33
                                 High-dose B vitamin \[[@B66]\]               409                40      27                   0.26            601        1.47
                                 Estrogen replacement \[[@B6]\]               120                39      32                   0.10            153        1.27
  Moderate-to-severe/Severe AD   Memantine \[[@B13]\]                         404                37      6                    1.82            589        1.46
                                 Memantine \[[@B12]\]                         252                32      9                    0.875           345        1.37
                                 Memantine \[[@B67]\]                         350                35      17                   0.59            547        1.56
                                 Donepezil \[[@B5]\]                          249                50      18                   0.28            334        1.34
                                 Donepezil \[[@B68]\]                         343                91      44                   0.09            543        1.58

^a^Recruitment rate statistic, number of participants per site per month. Reported numbers are gross estimates from data reported in publications rather than exact calculations of recruitment rates averaged across study sites. ^b^Number of patients screened for every enrolled subject. ^c^Failed to meet enrollment goals. AD, Alzheimer\'s disease; DHA, docosahexaenoic acid; NA, not available.

Visit frequency and study length
--------------------------------

Decisions related to the total length of a study and the frequency of study visits are guided by study goals and often by concerns over safety. It is logical to expect that the longer the study and the greater the number of study visits, the greater the burden on participants and the more difficult recruitment will be. Trials of agents with high risk profiles or for which the risk profile is largely unknown often require more visits to ensure patient safety. For example, early-phase studies (phase I or IIa) are often shorter (on the order of weeks to months) and require more frequent study visits than later-phase studies. Phase II AD trials of gamma secretase inhibitors have commonly used every-other-week study visits \[[@B1]\], making participation more daunting, especially for individuals who travel great distances to participate. In contrast, late-phase studies (phase IIb or III) that aim to evaluate efficacy are commonly at least 18 months long. These trials generally use study visits every 3 months. Less commonly, the intervention itself necessitates a more frequent rate of study visits. Ongoing trials of some immunotherapies for AD use medication infusions once or twice per month.

Selection of the targeted Alzheimer\'s disease population
---------------------------------------------------------

The target population is defined by the inclusion and exclusion criteria that participants must meet to enroll. Inclusion criteria should be designed to enroll only patients who truly suffer from AD and to maximize the likelihood of demonstrating a difference between drug and placebo when one exists \[[@B2]\]. Inclusion criteria generally identify a patient population of a specific disease severity. This is most often defined by a range of scores on the Mini-Mental State Examination (MMSE) \[[@B3]\]. Challenges in enrollment are not limited to trials of specific disease severities. As can be seen in the sample of published AD trials described in Table [1](#T1){ref-type="table"}, examples of studies with fast rates of enrollment (for example, RR \>1) exist for all disease severities. Similarly, slow enrollment can occur in trials in all stages of disease severity. Trials that fail to complete enrollment are also likely to go unpublished, given the probability that they will fail to meet the primary outcome \[[@B4]\]. To be clear, recruitment of participants with more severe disease faces unique challenges in comparison with studies of milder disease. Careful design and unique recruitment strategies, however, can be undertaken to overcome such challenges \[[@B5]\].

Besides disease severity, other specifications related to the population to be recruited can impact the rate of enrollment. For example, the Alzheimer\'s Disease Co-operative Study (ADCS) trial of estrogen replacement enrolled only women who had mild-to-moderate AD and who had undergone hysterectomy. Despite a somewhat wider range of MMSE inclusion criteria (12 to 28) than is typical, this trial enrolled only an average 10 subjects per month across 39 sites, and it took more than 3 years to complete enrollment \[[@B6]\].

Medication-related decisions
----------------------------

Criteria that exclude a large number of concomitant medications, though often necessary to ensure participant safety, can hinder recruitment. Many AD patients take supplements such as ginkgo biloba, and some trials exclude these patients. Alternatively, in trials examining available medications or supplements for therapeutic benefit in AD, the greater availability of these agents can pose a challenge to enrollment. The TRIMCI study of the anti-inflammatory agent trifusal in amnestic mild cognitive impairment (MCI) failed to meet its recruitment goals because of the high incidence of non-steroidal anti-inflammatory drug use among potential participants, which was exclusionary \[[@B7]\]. A recent trial of latrepirdine (formerly dimebon) excluded patients taking medications currently approved by the US Food and Drug Administration (FDA) for the treatment of AD. This study was conducted in part in the US, where there is a high prevalence of use of these prescription medications among those diagnosed with AD. The data related to recruitment for this trial are not yet available.

To increase the appeal to participants seeking new treatments, some studies incorporate alternate allocation, whereby randomly assigned participants have a greater chance of being assigned to an active treatment group than the placebo group. Although this may increase the appeal of participation to some patients, alternate allocation also requires increased sample size to maintain statistical power and it remains unclear whether this strategy abbreviates the total study recruitment period \[[@B8]\].

Design changes made after study initiation
------------------------------------------

Changes to study conduct after trial initiation but before the close of enrollment can impact recruitment. The original entry criteria for a phase III trial of tarenflurbil included mild-to-moderate AD patients with an MMSE score of between 15 and 26. Three months after enrollment began, the MMSE criteria for entry were changed to 20 to 26 as a result of findings from a phase II study \[[@B9]\]. Overall trial recruitment occurred from February 2005 until April 2008. Such changes mid-enrollment can counteract previous recruitment strategies. Similarly, stopping a study medication dose prior to closing enrollment is likely to impact recruitment. Dosing changes, especially those brought about by safety concerns, must be communicated to new participants as part of informed consent and may deter enrollment of new subjects. The high dose of the anti-amyloid antibody bapineuzumab was halted for safety reasons prior to closure of enrollment in a recent phase III study. Alternatively, the publication of positive data related to a study drug might improve enrollment. The same phase III study of bapineuzumab was still enrolling when data were published from phase II efficacy \[[@B10]\] and biomarker \[[@B11]\] trials. Data on the recruitment rates for the bapineuzumab phase III study are not yet available. Trials of drugs for which previous positive trials have been conducted are likely to enroll quickly. The initial trial of memantine in moderate-to- severe AD (MMSE 3 to 14) enrolled 252 subjects at 32 US sites over the course of 9 months \[[@B12]\] and demonstrated a significant difference from placebo on the primary efficacy outcomes. Consequently, a trial of memantine in moderate-to-severe AD (MMSE 5 to 14) patients taking donepezil efficiently enrolled 404 patients at 37 trial sites over the course of 6 months \[[@B13]\].

Barriers to recruitment impact Alzheimer\'s disease patients and their study partners and shape trial populations
=================================================================================================================

Successful trial enrollment faces many barriers, and most AD trials struggle to enroll. The ADCS trial of docosahexaenoic acid (DHA) enrolled 400 mild-to-moderate AD patients in 8 months, 10 months ahead of schedule, making it unique among AD trials. The agent tested in this trial funded by the National Institutes of Health was considered safe, allowing less restrictive inclusion and exclusion criteria. The trial also employed a 60/40 alternate allocation ratio toward active treatment. The factor that may have had the greatest impact on trial recruitment, however, was that it was conducted during a period in which few other trials in mild-to-moderate AD were recruiting and competition for subjects was minimal (Joseph Quinn, Oregon Health and Science University, Portland, OR, USA, personal communication).

As discussed, successful recruitment means more than just timely fulfillment of enrollment goals. Trial participants should be representative of the greater AD population. The mean age of participants in the DHA trial was 75.6 years. Fifty-three percent of participants were female. These demographic factors are fairly representative of the greater AD-suffering population. Participants in the DHA trial averaged 14.1 years of education. The over-representation of highly educated participants is common among AD trial populations \[[@B14]\] and stands in stark contrast to epidemiologic studies, which consistently demonstrate that less than 12 years of education is a significant risk factor for AD \[[@B15],[@B16]\]. In the DHA trial, 90% of participants were Caucasian. Faison and colleagues \[[@B17]\] examined the race of AD trial participants, comparing 737 ADCS trial participants with 10,800 industry- sponsored trial participants. The authors found that only 10% of ADCS and 3% of industry-sponsored trial participants were non-Caucasian \[[@B17]\]. Given that African-Americans and Hispanics are at greater risk for AD than Caucasians \[[@B18],[@B19]\] and that the proportion of AD sufferers who are of minority race or ethnicity will increase faster than that of Caucasians in coming decades \[[@B20]\], the low rates of minority enrollment in trials must be improved.

Among study partners in the DHA trial, 65% were female and 68% were spouses of the participant. The patient\'s primary caregiver most often fills the role of study partner and there are roughly 11 million persons in the US caring for a dementia patient. The majority of AD caregivers are women. Only a fraction of caregivers in the US, however, are spouses. The majority of caregivers are non-spousal family members, including primarily those who care for a parent or a parent-in-law \[[@B20]\]. The high representation of spousal caregivers in AD trials is striking and important. Trials offer patients and families an opportunity to feel active and involved in their medical care and in medical science\'s attempts to help them, others like them, and future generations. Many enroll in AD trials, however, in pursuit of therapeutic benefit. Spousal caregivers may have greater motivation than do adult children caregivers to pursue new therapeutic options. Alternatively, there may be increased barriers to participation for adult children caregivers, who are more likely to be working full-time, more likely to have young families, and thus less likely to have the scheduling flexibility to participate in clinical trials in the 9-to-5 clinic schedules in which they are generally conducted.

The overall differences between the enrolled population and the general AD population are troubling. They suggest that the barriers to recruitment and retention significantly shape the population under study and call into question the notion that the results of AD trials will be broadly applicable beyond a given study. We will next examine the various barriers to recruitment of AD trial participants, including the patient and the caregiver study partner.

Barriers related to the Alzheimer\'s disease patient-caregiver dyad
-------------------------------------------------------------------

The decision to enroll in an AD trial is made by two people: the patient and their study partner. In this way, recruitment to AD trials is twice as difficult as recruitment to clinical trials that enroll only the patient. Those who choose to participate in a clinical trial commit significant time and energy. This commitment is justified out of hope for personal and societal benefit and trust in the investigator and study site \[[@B21]\]. The commitment is made with an understanding of given risks and requirements. Both the patient participant and the study partner participant must give informed consent and both must commit to full participation. Of course, patientcaregiver dyads cannot choose to participate unless they are aware of studies. At diagnosis, referral to trials is uncommon \[[@B22]\]. Thus, participation by those seeing physicians who do not personally conduct trials often requires active pursuit of information about study opportunities. Yet even when the patient and the study partner are aware of trials, they are still likely to encounter several barriers to trial participation. The barriers and facilitators of AD trial enrollment related to patients and caregivers are summarized in Table [2](#T2){ref-type="table"}.

###### 

Facilitators and barriers to participation in Alzheimer\'s disease clinical trials

  Factor                                Impact   Participant affected   Description
  ------------------------------------- -------- ---------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Low trial awareness                   \-       B                      Those not aware of trials cannot participate.
  Comorbidities                         \-       P                      Patients with cardiovascular disease, cerebrovascular lesions, or other medical problems are likely to be excluded.
  Medications                           \-       P                      Patients taking a high number of prescription medications are likely to be excluded from participation. Specific trials may have other criteria (for example, excluding medications approved for AD) that prevent some patients from participating.
  Risks of side effects                 \-       B                      Risks associated with investigational therapies are barriers to patients and their study partners, who often identify risks to the patient as \'personal\' risk.
  Barriers associated with procedures   \-       P                      Patients may be unwilling to undergo procedures such as lumbar puncture, unable to undergo MRIs, or suffer associated frustration with cognitive testing.
  Risk of placebo                       \-       B                      Some dyads enroll primarily out of hope for access to new treatments. For these persons, the possibility of receiving placebo is a barrier to participation.
  Travel and other logistics            \-       B                      The requirement of attending study visits at the medical center can deter participation.
  Language barriers                     \-       B                      Only patients and study partners who both are capable of fluent communication in the language acceptable for participation are generally eligible to enroll.
  Informed consent                      \-       P                      Patients who are not aware of their impairment may lack the capacity to give informed consent.
  Informed consent                      \+       B                      Most trials allow a legally authorized representative to provide informed consent on behalf of the patient.
  Access to new treatments              \+       B                      Many participants enroll in trials in the hope of direct medical benefit for the patient.
  Altruism                              \+       B                      The desire to assist medical research is a commonly cited reason for participating in AD trials.

Impact: Facilitator (+), barrier (-). Participant impacted: patient (P) or both (B) patient and caregiver. AD, Alzheimer\'s disease; MRI, magnetic resonance imaging.

Barriers related to the Alzheimer\'s disease patient
----------------------------------------------------

Many AD patients who wish to participate in a clinical trial may not be eligible to do so. AD patients are, by definition, older. Older patients are likely to suffer from comorbidities that exclude participation. For example, current trials of immunotherapies exclude participants for a previous infarct (observed via magnetic resonance imaging \[MRI\]), even if it results in no neurologic sign or symptom. Given the high incidence of overlap between AD and vascular pathology \[[@B23]\], a substantial number of patients who might otherwise qualify for a trial may fail to be included, because of this criterion.

Older patients, especially in the US, also take a high number of prescription medications, which may similarly exclude participation. Even if these patients do not take an exclusionary medication at screening, trial protocols instruct investigators to enroll only patients whose medication profiles are stable and not likely to change through the course of the study. Protocols generally include patients taking AD medications, although these medications are subject to the same requirements. Thus, when enrolling mild patients who take only an acetylcholinesterase inhibitor (AChEI), the investigator is forced to consider whether to enroll the patient or start memantine (approved only in moderate-to-severe disease) to ensure stability through the course of the trial. Choosing the latter forces a delay in trial initiation and increases the likelihood that the patient will not be enrolled due to study closure or another reason.

Previous participation in an AD trial may exclude enrollment. Late-stage trials generally exclude participants of earlier-phase studies of the same drug. Similarly, most trials of active or passive immunization now exclude patients who have previously participated in a trial of any AD immunotherapy. In fact, for some ongoing trials, choosing to enroll means lifelong participation in one and only one trial. For example, the ADCS trial of nerve growth factor gene transfer aims to follow participants to autopsy and, given that subjects receive a therapy that is anticipated to deliver its therapeutic effect for as long as the neurons receiving it survive, being accepted into other trials is unlikely for recipients of the active therapy.

Some patients may be unwilling or unable to participate because of the procedures involved in a study. Individuals with pacemakers cannot undergo study-required MRIs and thus are excluded from trials that require imaging to ensure safety or use volumetric measures as mandatory outcomes. Many patients experience anxiety related to study procedures such as lumbar punctures. One phase II investigation of a gamma secretase inhibitor in prodromal AD is enrolling participants in the randomly assigned treatment trial only if they meet specific criteria related to cerebrospinal fluid protein analysis. Individuals unable or unwilling to undergo lumbar puncture are ineligible. Neuropsychological testing remains the hallmark of AD trials, co-primary outcome measures for all registration trials include one cognitive measure, and essentially all trials include a broad array of psychometric tests. For many trials, cognitive testing batteries are limited to the English language. Often, individuals not able to complete cognitive testing in the available languages at a study site are excluded. Such testing may require 3 to 5 hours to complete and can result in frustration and distress for the participant \[[@B24]\]. In subjects aware of their impairment, the reminder of their cognitive struggles can be overwhelming and may result in an unwillingness to participate.

Not all AD patients are aware of their impairment and those who lack insight may also lack the capacity to give informed consent. Some recent trials of aggressive therapies exclude individuals not able to demonstrate the capacity to provide consent. In these trials, the inability to comprehend trial-related procedures and risks is a barrier to participation. The majority of AD trials, however, facilitate participation by permitting a legally authorized representative to give the informed consent on behalf of a patient who lacks the capacity to do so for him- or herself. Most AD patients wish to be involved in the decision of whether to participate \[[@B25]\], and dyads that enroll in trials are likely to reach a joint decision. Although it is not clear how often it occurs, disagreement between patients and caregivers about participation can be a barrier to enrollment \[[@B21]\].

Barriers related to the study partner
-------------------------------------

Patients who do not have a suitable study partner cannot be enrolled in AD trials. The study partner must be an individual familiar with the patient\'s medical and personal situation and the primary caregiver most often fills this critical role. At screening, the study partner provides an accurate medical history. Following enrollment, they provide transportation to study visits and serve as informants in a variety of study procedures and outcome measures. Between study visits, they monitor study and medication adherence.

The role of the caregiver in the decision to participate in an AD trial is as important as that of the patient. Often, caregivers choose to participate in AD clinical trials out of hope for medical benefit for the patient \[[@B21],[@B26]-[@B28]\]. Other motivations include desperation resulting from a lack of other treatment options \[[@B21],[@B26]\] and a desire to help medical science pursue a cure \[[@B21],[@B26],[@B27],[@B29],[@B30]\]. Trials offer the opportunity to interact with AD experts and access to new technologies that might not be covered by insurance.

If a study partner faces insurmountable barriers to participation, then it is unlikely that the patient will participate. Caregivers who decline participation cite a variety of factors that lead to their decision. Some caregivers cite the need to travel to the study site \[[@B21]\], and offering car services to facilitate transportation or performing at least a portion of study visits in the home increases the likelihood that caregivers will support a decision to participate \[[@B31]\]. Individuals who report travel as a barrier, however, are not necessarily those who reside furthest from study sites. This suggests that, at least for some caregivers who decline participation, emotional and attitudinal factors about the logistics of travel play a large role.

Caregivers also face emotional burdens \[[@B32]-[@B34]\]. They often cite the fear of side effects for the patient as a barrier to participation \[[@B21],[@B28]\]. Many caregivers do not distinguish risks or benefits for the patient from risks or benefits for themselves \[[@B21]\]. The patient is most often a spouse or parent, and the caregiver does not wish to increase the patient\'s medical burden. Furthermore, increased medical burden for the patient is increased burden on the primary caregiver.

Finally, some caregivers cite the risk that the patient will not benefit from participation as a barrier to enrollment \[[@B27]\]. Some caregivers who decline enrollment cite doubts about the potential efficacy of the agent under investigation as reason for refusing participation \[[@B28]\]. These caregivers may defer participation in one trial to participate in another, more promising study. The same individuals are likely to cite the \'risk\' of placebo as a deterrent to participation.

What factors impact trial retention?
====================================

Regulatory and ethical guidelines mandate that participants can withdraw their consent to participate in a clinical study at any time. Therefore, good retention begins prior to enrollment, by recruiting study participants who are likely to complete a trial. Once trial conduct is initiated, making participation as convenient as possible for subjects and study partners optimizes retention.

Steps should be taken to inform participants of their value and the value of the research in which they are participating. Newsletters informing participants of trial progress can facilitate the feeling of being part of a larger agenda. For centers or investigators conducting multiple trials, annual luncheons honoring research participants can be effective retention tools, although these events must be conducted with sensitivity to participant confidentiality and privacy.

A variety of factors can impact trial retention. Examples of trials that had poor retention exist, but often these trials faced extenuating challenges. A trial in mild-to-moderate AD of atorvastatin enrolled 98 participants, of whom 15 withdrew consent prior to random assignment \'primarily to participate in other trials\' \[[@B35]\]. Similarly, the ADCS trial of dihydroepiandrosterone initially recruited 58 participants, but only 33 completed the 12-month trial \[[@B36]\]. Fifty-three percent of subjects randomly assigned to placebo dropped out of the study prior to completion, and the authors hypothesized that the high rate of dropout may have been the result of the widespread availability of FDA-approved AChEI therapies during study conduct \[[@B36]\].

We examined the retention rates in a sample of AD trials (Table [3](#T3){ref-type="table"}). Although some trials may include a low dose without expectation of therapeutic benefit, we chose to combine all active treatment doses in a single category. In the very few occasions in which two active treatments were tested against placebo \[[@B37],[@B38]\], we combined all active treatments in a single group. In cases in which participants completed a study off-medication, they have been included as completers whenever possible. Importantly, this summary is limited largely to trial reports in primary manuscripts rather than analysis of raw data and should be interpreted accordingly.

###### 

Retention rates from a sample of Phase II and Phase III Alzheimer\'s disease clinical trials

                                 Treatment under study                          Study enrollment   Active completers   Placebo completers   Trial length, months
  ------------------------------ ---------------------------------------------- ------------------ ------------------- -------------------- ----------------------
  Mild cognitive impairment      Rofecoxib \[[@B54]\]                           1,457              687/725 = 0.95      702/732 = 0.96       48
                                 TRIMCI study of trifusal \[[@B7]\]             257                104/129 = 0.81      119/128 = 0.93       18
                                 Donepezil \[[@B57]\]                           270                90/133 = 0.68       114/137 = 0.83       6
                                 Vitamin E and donepezil \[[@B38]\]             790                346/510 = 0.68      193/259 = 0.74       36
                                 Rivastigmine \[[@B55]\]                        1,018              312/508 = 0.61      346/510 = 0.68       48
                                 Donepezil \[[@B58]\]                           821                226/409 = 0.55      273/412 = 0.66       12
                                 Two studies of galantamine \[[@B56]\]          2,057              476/1,029 = 0.46    543/1,028 = 0.53     24
  Mild-to-moderate AD            Dimebon \[[@B59]\]                             183                78/89 = 0.88        77/94 = 0.82         4
                                 Gamma secretase inhibitor \[[@B62]\]           51                 32/36 = 0.89        12/15 = 0.80         4
                                 Rosiglitazone \[[@B65]\]                       518                106/122 = 0.87      336/389 = 0.86       6
                                 High-dose B vitamin \[[@B66]\]                 409                204/240 = 0.85      140/169 = 0.83       18
                                 Rivastigmine patch \[[@B63],[@B64]\]           1,195              704/893 = 0.79      266/302 = 0.88       6
                                 Estrogen replacement \[[@B6]\]                 120                65/81 = 0.80        32/39 = 0.82         15
                                 Galantamine \[[@B69]\]                         978                539/692 = 0.78      240/286 = 0.84       5
                                 Rofecoxib \[[@B37]\]                           351                179/240 = 0.74      88/111 = 0.79        12
                                 DHA (Joseph Quinn, personal communication)     402                178/241 = 0.74      129/161 = 0.80       18
                                 Bapineuzumab \[[@B10]\]                        234                92/122 = 0.75       87/107 = 0.81        18
                                 AN1792 \[[@B61]\]                              372                223/299 = 0.74      53/73 = 0.73         12
                                 Idebenone \[[@B60]\]                           536                281/407 = 0.69      96/129 = 0.74        12
                                 Atorvastatin \[[@B39]\]                        640                207/314 = 0.66      245/326 = 0.75       18
                                 Galantamine \[[@B70]\]                         636                266/423 = 0.63      172/213 = 0.81       6
                                 Tarenfl urbil \[[@B9]\]                        1,684              506/862 = 0.59      540/822 = 0.66       18
  Moderate-to-severe/Severe AD   Selegeline/Alpha tocopherol \[[@B71]\] CDR 2   341                240/257 = 0.93      78/84 = 0.93         24
                                 Donepezil \[[@B72]\] MMSE 5 to 17              291                121/144 = 0.84      126/146 = 0.86       6
                                 Donepezil \[[@B5]\] MMSE 1 to 10               249                95/128 = 0.74       99/120 = 0.82        6
                                 Memantine \[[@B67]\] MMSE 5 to 14              350                134/178 = 0.75      126/172 = 0.73       6
                                 Memantine \[[@B12]\] MMSE 3 to 14              252                97/126 = 0.77       84/126 = 0.67        7
                                 Donepezil \[[@B68]\] MMSE 1 to 12              343                117/176 = 0.66      127/167 = 0.76       6
                                 Memantine \[[@B13]\] MMSE 5 to 14              404                172/203 = 0.85      150/201 = 0.75       6

AD, Alzheimer\'s disease; CDR, Clinical Dementia Rating; DHA, docosahexaenoic acid; MMSE, Mini-Mental State Examination.

Table [3](#T3){ref-type="table"} shows that the majority of subjects who enroll in AD trials are retained through trial completion and that, across disease severities, these rates do not substantively vary. MCI trials had an average retention rate of 71.6%, mild-to-moderate AD trials 77.7%, and moderate-to-severe and severe AD trials 75.4%. One might expect that, independent of disease severity, retention is easier in shorter trials. Even among some of the longest trials conducted, however, retention rates are high. Alternatively, some of the lower rates are for 6-month studies.

Few of the trials we sampled had a significant difference between the treatment and placebo groups in the percentage of participants who completed the trial \[[@B13],[@B39]\]. This supports the idea that altruism is a motivating factor for enrolling and continuing participation. If a patient or caregiver was interested in participation solely for the sake of gaining access to a new therapy, they might be likely to drop out of a trial if they concluded that they were randomly assigned to the placebo group (whether they were correct or not) or if they perceived that the patient is declining despite receiving study medication.

Recent analyses of the ADCS MCI trial of donepezil and vitamin E by Edland and colleagues \[[@B40]\] suggest that a variety of factors within a trial may indicate patients who will drop out prior to study completion. The authors found that the characteristics of participants who were likely to drop out were non-Caucasian race, less than high school education, and being unmarried (that is, having an adult child or child-in-law as a study partner). Furthermore, the analysis suggested that participants recruited to commercial trial sites (as opposed to academic sites) were at increased risk to drop out of a trial. Dropout rates at commercial sites were nearly double those of sites that were AD research centers funded by the National Institute on Aging \[[@B40]\]. In line with their analyses, in the trials that we reviewed, those with the largest study size (and as such were most likely to enlist non-academic sites) had the lowest retention rates. Trials with a sample size of greater than 1,000 had a mean retention rate of 70.6%. Alternatively, the smallest trials examined (fewer than 300) had higher rates of retention (81.4%). Similarly, trials conducted by the ADCS had an 81.2% mean retention rate. The remaining trials averaged a 73.2% retention.

Outlook for the future
======================

What is the available pool of patients for Alzheimer\'s disease trials?
-----------------------------------------------------------------------

Many promising therapies are in clinical development for AD and more will enter clinical trials in coming years. To plan the recruitment of adequate subject populations for these trials, it will be necessary to better understand the pool of eligible patients qualified to participate. More than 400,000 Americans are diagnosed with AD annually \[[@B41]\]. Hence, investigators might assume that they have an ample (and growing) supply of participants for trials. Among all dementia patients, however, roughly half are moderately severe or more advanced in their disease \[[@B42],[@B43]\] and therefore fail to meet the mild-to-moderate category for which most trials currently recruit. The majority of all AD patients are older than 75 years \[[@B43]\], increasing the likelihood of exclusion for reasons such as comorbidities or prohibited medications. In fact, analyses of general clinical AD populations suggest that only 10% to 13% are eligible for clinical trials \[[@B44],[@B45]\]. In sum, the pool of eligible trial participants for AD trials is limited.

In 2009, at least seven phase III trials (of five drugs) recruiting in the US required a combined total of 8,510 participants (solanezumab \[LY2062430\] *n*= 1,000 \[ClinicalTrials.gov ID NCT00905372\] and *n*= 1,000 \[NCT00904683\]; semagecestat \[LY450139\] *n*= 1,100 \[NCT00762411\] and *n*= 1,700 \[NCT01035138\]; bapineuzumab *n*= 1,300 \[NCT00574132\] and *n*= 1,000 \[NCT00575055\]; dimebon *n*= 1,050 \[NCT00829374\]; and intravenous immunoglobulin *n*= 360 \[NCT00818662\] \[[@B1]\]). There were more, though smaller, phase II studies. Screening ratios are generally better than 2:1 (2 patients screened to enroll 1) (Table [1](#T1){ref-type="table"}), but the fact remains that a significant number of patients recruited will not be enrolled. Thus, if one considers the newly diagnosed patients each year, the barriers to enrollment, and the number of participants needed as multiple trials are conducted simultaneously, it is clear that the recruitment needs for AD clinical trials will remain a challenge that results in competition for eligible subjects. Strategies to overcome the current barriers to recruitment must be developed.

How can trial recruitment be optimized?
---------------------------------------

The most straightforward approach to improving the rate of enrollment is to increase the number of trial sites. AD trials have become increasingly \'global\', enrolling from multiple countries and continents within single studies. This change brings potential methodological \[[@B46]\] as well as ethical challenges when less industrialized nations are involved for which access to the drug (once it is approved) is not likely \[[@B47]\] (Declaration of Helsinki). Moreover, trial recruitment is difficult in all countries, not just the US \[[@B48]\]. It has been shown that, with increasing trial site number, the likelihood of placebo decline is reduced \[[@B49]\]. Furthermore, expanding the number of trial sites results in the inclusion of sites that are not focused on AD as a therapeutic area.

AD trials are optimally performed at trial sites experienced in their specific conduct by staffs well versed in the issues AD patients and their families face. Trials can be designed to facilitate participation for the subject and their study partner. Performing visits in the home and otherwise limiting travel hassles will increase the willing-ness to participate among caregivers.

Awareness of trials must be increased. Efforts to increase awareness should target both patients and caregivers. The fact that most caregivers are adult children but most study partners are spouses indicates that there remains a large number of uninformed or unwilling potential participant dyads. Social media may provide an avenue to specifically target adult children caregivers. The Wisconsin Registry for Alzheimer\'s Prevention has successfully enrolled more than 1,400 middle-aged adult children of AD patients in a natural history study \[[@B50]\], and the use of television advertising has been an effective means of recruitment. Similarly, web-based patient registries such as <http://www.patientslikeme.com>\[[@B51]\] have been used effectively in other therapeutic areas. Internet use among those over the age of 65 is increasing, and \'wired seniors\' are likely to seek health-care information specifically when online \[[@B52]\]. AD models of registries have been proposed and could target MCI and mild-stage AD potential participants and caregivers and also potential participants in prevention trials, such as baby boomers \[[@B53]\].

The advantage of disseminating the message of the value of clinical trials is to diversify the reasons why people enroll. The more reasons a person has for being in a trial, the more likely he or she is to enroll and, over time, stay in a trial. As participants experience adverse events and the efforts of study visits, those participants whose reasons for enrollment include trust in the investigator and a desire to help others are more likely to stay in a trial than are patients whose sole motivation is benefit to their health. This is especially true in AD clinical trials in which, to date, therapeutic benefit has been elusive.

Effective methods to limit competition among trials, facilitate enrollment, and match eligible candidates with appropriate trials would improve recruitment and retention and result in a more rapid drug development. Agencies to fill such needs could have a major impact on clinical research. Such agencies, however, should be supported by federal and state governments, not for-profit entities, and would thus be free of private corporate interests.

Conclusions
===========

In summary, clinical trials in AD face a variety of challenges to recruitment and retention. Many trials struggle to complete enrollment in a timely fashion despite substantial effort. Trial enrollment may not represent the greater disease-suffering population, and this may result in trial findings that are not readily applicable beyond the study. AD trial retention is largely effective, although some variation does exist and is likely related to the population recruited and the caliber of study conduct. Responses to these challenges and improvement to recruitment and retention can and should be made. All eligible subjects must be made aware of participation opportunities, and trials must be designed in a manner that makes participation feasible for patient-caregiver dyads.
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